Deep Percutaneous Penetration into Muscles and Joints: Update by Doktor, Vladyslava et al.
  
 
International Journal of Drug Delivery 5 (2013) 245-256 
http://www.arjournals.org/index.php/ijdd/index 
 
Review Article 
             
Deep Percutaneous Penetration into Muscles and Joints: Update 
Vladyslava  Doktor1,2, Christine M. Lee2, Howard I.Maibach2 
 
*Corresponding author: 
 
Vladyslava  Doktor  
 
1Touro College of Osteopathic 
Medicine, New York 
2Department of Dermatology, 
University of California San Francisco, 
90 Medical Center Way, Box 0989, San 
Francisco, CA 94143-0989 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A b s t r a c t  
Transdermal drug delivery is a multifactorial process with variable penetration mechanisms.  
Adverse effects associated with nonsteroidal anti-inflammatory drugsÊ (NSAIDs) use in treatment for 
joint and muscle diseases are sufficiently severe to consider topical application.  A drug's 
lipophilicity, fraction unbound and permeability found in the viable skin are some of the 
physiochemical factors influencing the delivery mechanism of transdermal absorption. These and 
other variables play a role in determining if the drug reaches the deep tissues via direct penetration 
from dermal or systemic blood redistribution.  Pharmacokinetic models have been developed to help 
elucidate penetration routes and efficacy for various drugs. Improvements in modes of transdermal 
delivery through active research projects including relevant animal models and human translational 
research may introduce advances in clinical development of treatments.  
Keywords: topical administration; non-steroidal anti-inflammatory agents; skin absorption; 
percutaneous drug delivery 
Introduction 
Percutaneous delivery of drugs into deeper tissues for the 
treatment of inflammatory muscle, joint and tendon diseases is a 
much discussed, but not fully educated topic.  With many now  
 
 
living past the 70s; the age when the risk levels for inflammatory 
diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA) 
increase, the need for an efficient and transdermaly delivered 
medication is substantial.[1]  Since oral NSAIDs pose a risk of 
adverse effects such as renal, hepatic, cardiac, and 
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gastrointestinal toxicity, topical use of NSAIDs is necessary.  The 
benefit of a transdermal therapeutic system (TTS) results in a 
bypass of the gastrointestinal tract and associated side effects.  
Steps the topical compounds take to reach the joints and 
underlying muscular tissue are partition and diffusion, primarily 
through the outermost skin layer, stratum corneum (SC), 
epidermis, dermis and subcutaneous fat. The challenge remains 
to overcome the resistance of SC and of course, to reach the 
deeper tissue without losing much of the compoundÊs 
concentration to cutaneous microcirculation.  However, earlier 
work showed that local subcutaneous drug delivery is viable and 
can be effective.[2]  Novel approaches to enhance the penetration 
of the SC and transdermal drug delivery are now available.[3] 
Penetration mechanisms and efficacy of absorption of topically 
applied drugs have reached new heights.  Pharmokinetic 
properties of topical NSAIDS have been studied in length as they 
are the main focus for the local treatment of several inflammatory 
diseases of joints and muscles.[2]   Some common NSAIDS are 
salicylic acid (SA), diclofenac, ketoprofen and naproxen. 
Diclofenac is the only drug in the group of NSAIDS approved for 
use in the United States. Available formulations are diclofenac 
epolamine topical patch 1.3%, diclofenac sodium topical gel 1%, 
and diclofenac sodium topical solution 1.5% w/w in 45.5 % 
dimethyl sulfoxide (DMSO). The latter two are specifically 
approved by the United States Food and Drug Administration for 
osteoarthritis treatment.[4] 
 
Following from a previously published review of percutaneous 
penetration new advances in skin barrier function, 
physicochemical, pharmokinetic and physiological factors that 
ground the transdermal administration have been made and are 
discussed in detail here.[5]   The groundwork for determining 
bioequivalence via kinetics has not been laid.  
Drug Properties Affecting Distribution 
As a drug transports through the first barrier, SC, passive diffusion 
serves as a main mode.  Whether it is via intercellular or 
transcellular pathway, factors mostly involved are lipophilicity and 
permeability.[6]   Other important factors affecting absorption 
include drug molecular size and water solubility, vehicle, skin 
integrity, which mainly is affected by the disease, body site and 
age.  
Lipophilicity 
Lipophilicity is defined by log P, the logarithmic octanol-water 
coefficient.[7]   High lipophilicty is needed to overcome SC barrier 
and to penetrate to deeper tissues.  The higher the lipophilicty the 
deeper the solute will be transported.  It is also directly 
proportional to increase in log P.[8]   For example, the lipophilic 
salt of SA, triethanolamine salicylate (TEA), penetrated more 
efficiently into muscle compared to ionized SA.[9]  Another study 
performed in vivo on male rats demonstrated almost two- fold 
greater penetration of a lipophilic derivative of SA (10% TEA)  
compared to the less lipophilic derivative than TEA, 10% methyl 
salicytate, with the topical application of the two compounds  on 
the abdomen of male rats.  
If the solution is not sufficiently lipophilic to penetrate the SC 
enhancers such as propylene glycol, alcohol, dimethyl must be 
utilized.  Diclofenac sodium 1% gel uses isopropyl alcohol, 
propylene glycol and water to accelerate drug penetration of the 
skin.  The alcohols typically promote drug solubility and also aid in 
permeation of the SC.  However, higher concentration of alcohol 
may cause SC dehydration, which will in return impact drug 
permeability.[10] 
Permeability  
Another drug property contributing to the penetration ability to 
underlying muscles and joints is 
permeability,[11]  which can be measured by the permeability 
coefficient, kp. Permeability coefficient increases with an increase 
in the fraction of unionized drug,[12]  and has a parabolic 
relationship with log p, the lipophilicity of a compound[2] for 
several NSAIDs, as reported in an in vitro study of human 
cadaveric skin from the mid abdomen following delivery of the 
drug via a donor compartment.  An optimal log p value will yield a 
peak permeability coefficient.  This observation suggests that a 
hydrophilic-lipophilic balance is required for deep penetration of 
drugs.[2]  By taking the product of kp and the solubility of the drug 
in a given vehicle, the maximum flux, Jmax, through the skin can 
be calculated.  However, a study showed that molecular weight 
(MW) is a more significant determinant of maximal flux than 
kp.[13] 
Molecular Weight 
Previously, MW was not believed to be a significant determinant 
of transdermal drug delivery.  Even though earlier studies showed 
that with increasing MW, clearance of the drug from viable skin 
into the muscle decreases, results were not statistically 
significant.[14]  A review of Jmax versus several parameters of the 
drug including MW, solubility in octanol, octanol/water partition 
coefficient, ultimately showed that MW was the dominant 
determinant of Jmax, with the following regression relationship: log 
Jmax = -3.90 to 0.0190 MW(r2=0.847, p<0.001).[13]   Data was 
gathered from several experiments performed on human skin in 
vitro. The results changed previous views on which factors affect 
the maximal flux and transdermal drug distribution. 
Fraction Unbound Drug in Viable Skin 
Interestingly, unbound fraction of drug in viable skin (fuvs) had 
statistically significant positive correlation (p<0.005, R2 = -0.63) 
with the drug clearance from viable skin to the muscle 
(Table 1).[14]  As fuvs increased, an increased in clearance from 
the viable skin into the muscular layer was observed. The study 
was performed on stripped-skin rats in vivo after application of 
drug to the ratÊs abdomen via a donor cell for 0.5,1, 2, 3, 4, and 7 
h.  In viable skin, drugs may bind to the cytosolic components, 
influencing direct penetration.[15]   When a drug is not bound to 
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proteins or lipids, the molecule diffuses more easily into deeper 
tissues including the muscle.  However, it is not known why the 
increase in fraction of unbound drug in viable skin is not an 
important factor for systemic absorption.  Perhaps the equilibrium 
between the unbound fraction among the viable skin, muscular 
layer, and plasma may play a role.[14] 
Relative Importance of the Physicochemical Factors 
Among the factors presented above, it seems that the fraction 
unbound in viable skin is important for the direct penetration of a 
compound.  Penetration rate was characterized by a kinetic 
parameter, kdirect, which was found to correlate with the clearance 
from the viable skin to  muscle.[14]  Multiple linear regression 
analysis was then used to determine the relative contribution of 
MW, log p, and fuvs on the penetration rate.  The results were 
0.1588 for MW, 0.2686 for log p, and 0.5726 for fuvs.[14]  This 
analysis showed that fuvs had the greatest contribution to the 
penetration rate, as measured by kdirect. 
Pharmacokinetic Models 
One of the first pharmacokinetic models was developed in 1982, 
which was a four compartment model with the epidermis, dermis, 
capillaries, and urine using first order kinetics.  Two fixed rate 
constants were used to characterize absorption and elimination, 
while two variable rate constants helped define the penetration 
through the viable skin and the competition for the drug between 
the viable skin and the stratum corneum. Guy et al. found that 
topical delivery produces high local subcutaneous levels of drug 
despite reduced blood concentrations.[16]   Direct deep 
penetration is thus the mechanism implicated.  The blood flow in 
skin, particularly in dermis, is a crucial factor in deciding the direct 
penetration of drugs into muscle.  On the one hand, blood vessels 
in the dermis absorb and dilute most compounds passing the 
epidermis, keeping a ÂÂsinkÊÊ condition and promoting 
percutaneous absorption.[17]  On the other hand, blood flow 
prevents drugs from directly penetrating into deeper tissues by 
removing them to the systemic circulation.  Absorption can also 
be modified by vasoconstrictors.  A recent vivo study on rats by 
Higaki et al. showed that topical application of a vasoconstrictor, 
phenylephrine, enhanced the direct penetration of the drugs into 
viable skin and muscle.[18]  Phenylephrine was co administered 
with several drugs via a donor cell, and the drugsÊ concentrations 
measured after 2 h of application time on the ratÊs abdomen.  
Distribution of antipyrine (p<0.001), SA (p<0.001), and diclofenac 
(p<0.01) into viable skin yielded statistically significant increase in 
penetration when phenylephrine was co administered versus 
control.  Similar results were seen for distribution into the muscle 
layer: antipyrine (p<0.001), SA (p<0.01), and diclofenac 
(p<0.05).[18] 
 
Multiple groups have analyzed drug distribution kinetics following 
percutaneous delivery.  Singh et al. developed a pharmacokinetic 
model using multiple differential equations to estimate the drug 
concentrations found below the epidermis after topical application 
of a drug.[19]  Importance of the pharmacokinetic model is that it 
can predict the amount of drug that eventually will reach the deep 
tissue compartments, providing useful information for the 
development of controlled dosing methods.  
 
Distribution to underlying tissues was modeled as multiple 
compartments in series, with the dermis and deep muscle in 
contact with the systemic circulation.  Separate differential 
equations were developed to characterize drug concentration in 
four or more compartments: the application cell, the dermis, the 
underlying tissue, and the systemic circulation.[19] 
Experimental Methods 
Drug solutions were applied to rats and subsequently the 
underlying tissue concentrations and clearance values were 
taken.  Since rats and humans have somewhat similar 
permeability characteristics, animal models were used to examine 
the pharmacokinetic properties of the drug after percutaneous 
delivery.[20]  Solutions were applied to exposed rat epidermis in 
absence of SC.  A glass cell containing the drug solution was 
attached to the exposed dermis, and was removed at 
predetermined times to measure solute concentration.  Blood 
samples were taken from the tail vein. Afterwards, the animals 
were sacrificed and tissues below the treated site were dissected 
to analyze drug concentrations.[7]  
 
 
Table 1.   Effect of Physiochemical Prameters on CLvsĉm and Peak Muscle Concentration*
Drug MW (g/mol) fuvs CLvsĉm (mL/h) Peak Muscle Concentration (nmol/g)a 
Diclofenac 295.1 0.592 0.008μ0.000 6.0μ0.5
Salicylic acid 138.1 0.870 0.085μ0.004 40μ5
Ketoprofen 254.3 0.701 0.133μ0.069 15μ2
Felbinac 212.2 0.667 0.043μ0.000 19μ2
Flurbiprofen 244.3 0.401 0.032μ0.000 33μ5
The clearance of a drug from the viable skin into the muscle, CLvsĉm , and peak muscle concentration  
are examined in relation to the molecular weight, MW, and the fraction of unbound drug found in viable 
 skin, fuvs. The study was performed on stripped-skin rats in vivo after application of the drug to the ratÊs abdomen via a donor cell. The rats were sacrificed at 0.5, 1, 
2, 3, 4, and 7h. 
*Data from [14];  aPeak muscle concentration estimated from  Higaki et al., Figure 3.[14] 
  
 
Model Predictions 
The model predicted tissue concentrations of different NSAIDs, in 
some cases within 90% of actual value.  With indomethacin, 
however, there was a higher observed value than predicted, 
suggesting that indomethacin has poor diffusiblity and 
accumulates in the dermis. [7]  Inaccuracies in the predictions 
may be due to inherent differences in tissue affinities for different 
solutes, nonlinearities in tissue binding (although trace 
concentrations of all solutes were used to avoid the nonlinearities 
in plasma and tissue binding), variations in plasma protein 
binding, dermis water partitioning, tissue-plasma partitioning, and 
possible drug effects on membrane or blood flow.  The apparent 
tissueătissue clearances may also vary for different compound[7]. 
 
 
 
 
Table 2.   Relative Contributions of Different Penetration Mechanisms for NSAIDs*
Drug Direct Penetration (%) Distribution from Systemic Circulation (%) 
Diclofenac 79.0 21.0
Salicylic acid 72.0 28.0
Ketoprofen 69.4 30.6
Felbinac 43.3 56.7
Flurbiprofen 62.5 37.5
The relative contribution of two delivery routes was calculated based on curves derived from  
HigakiÊs six-compartment pharmacokinetic model. The study was performed on stripped-skin   
rats in vivo after application of the drug to the ratÊs abdomen via a donor cell.  
*Taken from Higaki et al.[14] 
 
 
 
Table 3.   Comparison of Two Different Pharmacokinetic Models
 Singh and Roberts [7] Higaki et al. [14] 
No. of compartments 9 6 
Model arrangement Donor cell and deep tissue 
compartments in series arranged in 
parallel to plasma 
Donor cell, viable skin, and muscle in 
series arranged in parallel to both plasma 
nad contralateral skin, muscle 
Experimental studies In vitro human study on epidermal 
penetration 
In vitro human study on epidermal 
penetration 
 In vivo rat study on transdermal 
absorption 
In vivo rat study on transdermal 
absorption 
Parameters from in vitro studies kp (epidermal permeability coefficient)
Log p (lipophilicity) 
kdirect (penetration rate constant from 
viable skin to muscular layer) 
fuvs 
Application To predict deep tissue concentrations 
and compare with observed values 
To formulate standard curves to 
approximate the decreasing 
concentrations in deep tissues 
Statistical significance N/A CV ranges from 0.1% to 13%, R2 greater 
than 0.994 for standard curves 
Two of the pharmacokinetic models used to approximate deep tissue drug contcentrations with differential equations and nonlinear 
regression analysis. The experimental methods, applications, and statistical sifnificance of the results are examined. 
 
 
 
Higaki et al. also developed a pharmacokinetic model, this time 
with six compartments including 
contralateral skin and contralateral muscle, which were not 
included in the Singh et al. model.[14]  Inclusion of the 
contralateral side allows the contribution of the absorption from 
the systemic circulation to the muscular disposition to be 
evaluated more precisely.  In vivo rat transdermal studies were 
performed by comparing model predictions to experimental 
results. 
 
Unlike Singh et al., linear differential equations were used to plot 
standard curves (drug concentration over time) rather than 
estimate deep tissue concentrations.  For each standard curve, 
coefficient of variations ranged from 0.1% to 13.0%, and the 
squared correlation coefficient was over 0.994 for all the model 
drugs used.[14]  The standard curves fit the lines well, and 
Doktor et al. International Journal of Drug Delivery 5(3) 245-256 [2013] 
 
PAGE | 249 |
 
correlate significantly with the observed values for all six drugs.  
Having the standard curves enabled the calculation of the relative 
contribution of direct penetration of the drug based on the area 
under the curve values (Table 2).  Thus, the two models appear 
useful for analyzing and describing the transdermal disposition of 
drugs after topical application, though there may be slight 
variations in the way the differential equations are utilized (Table 
3). 
New Physiological Models 
Earlier pharmokinetic models created by Singh and Roberts, and 
Higaki et al. assumed that for solute is transported to deeper 
layers by molecular diffusion only.  Kretsos et al. reanalyzed the 
data and confirmed the consistency with their own similar 
distributed diffusion-clearance model.[21]  Following the previous 
research, Kretsos and Kasting created a new model to explain the 
dermal capillary clearance process based on assumed periodic 
microscopic distribution of dermal capillaries in three-dimensional 
space.  The downfall of this model is that it only applies to the 
steady-state scenario and explains localized concentration in 
dermis.[22]   Bound by the inability to recreate in-vivoconditions 
using in-vitroexperiments and invasiveness associated with the 
collection of such data via biopsy the contributory research is 
difficult to carry out.  However, a breakthrough came when 
Anissimov and Roberts determined that the deep percutaneous 
transport of drug cannot be attributed to diffusion alone and 
offered a new two-compartment model that considers blood 
and/or lymphatics, in addition to molecular diffusion to be involved 
in the transport to deeper tissues.  More specifically, they focused 
on the effect of blood flow, blood protein binding and dermal 
binding exert on the rate and depth of percutaneous penetration 
of topical drugs.  Unlike Singh and Roberts, and Higaki et al., in 
applying their model they used the combination of human biopsy 
data collected by Schaefer and colleagues[23-27] and their own 
human in-vitro dermis penetration experiments to obtain dermal 
diffusion/dispersion coefficient, and dermal blood clearance rate 
of 6 solutes.  Schaefer and colleagues collected human tissue 
concentration-depth profile of drugs in-vivoafter topical 
application. 
 
The term dispersion implies transport of solute by both blood and 
diffusion in the dermis.  They recognized that in order for 
convective blood flow transport to significantly impact the 
transport to deeper tissues, there must be sufficient binding to 
plasma proteins and blood flow, as the surface area of blood 
vessels is much less than that of the dermal matrix through which 
diffusion transport will occur.  Therefore, the contribution of 
dermal blood flow transport is likely to be noticeably decreased 
when there is vasoconstriction.[28]   They analyzed human dermal 
distribution data from previous micro dialysis experiments and 
recorded similar findings.  One limitation of their analysis was the 
assumption of no contribution of topically absorbed drug into the 
systemic circulation contributing to the underlying tissue 
concentration on recirculation.  It is considered to occur at long 
times and most considerable contribution to tissue concentrations 
deep below the treated site.[28] 
 
Dancik et al. further expanded on the findings by Anissimov and 
RobertsÊ physiological pharmokinetic model in that it recognized 
the interstitial convection associated with capillary flow and 
draining of the interstitial space.  Their new comprehensive model 
described drug diffusion in the extravascular tissue space tissue 
and vascular binding, axial (into the tissue) vascular, lymphatic 
and interstitial convection transport and constant radial 
(clearance) vascular transport, with the assumption of high 
capillary permeability.  This was done by comparing the in-vitro 
penetration lag times of diclofenac and nicotine gathered from 
their in-vitro experiments to those reported in-vivo penetration lag 
times in the dermis and deeper tissues.[29] 
 
They concluded that transport of highly plasma protein bound 
drugs into deeper tissues increases by several orders of 
magnitude faster than predicted by passive dermal diffusion.  
Although considerable concentration-depth gradient is evident for 
poorly protein bound drugs, it is nonexistent for highly bound 
drugs in the papillary dermis and small in the reticular dermis.[29]  
Highly protein bound drugs bind to collagen and albumin in the 
dermis.  The convective transport of albumin into lymphatic 
vessels that run deeper in subcutaneous tissue encourage deeper 
transport (Fig. 1 abstract). 
Distribution in Deeper Tissues 
Direct Versus Indirect Penetration 
NSAIDs directly penetrate to a depth of 3ă4 mm, with the 
systemic blood supply accounting for penetration into the deeper, 
underlying tissues.[19]  Drug levels peaked between 2 h and 4 h 
due to direct NSAID penetration.  At around 10 h, drug levels 
peaked again, this time due to the systemic blood supply 
redistributing the drug.[19] 
 
Higaki et al. also examined drug penetration distribution after 
topical application.[14]  Similar to Singh and RobertsÊ findings, 
also performed in vivo on rats,[19]  they determined that direct 
penetration was the predominant mechanism during the early 
period after starting the absorption study.  There is variability 
between the drugs in regards to concentration of the direct 
penetration into muscle after topical application.  For instance, the 
muscular disposition of diclofenac was almost all attributed to the 
direct penetration (90.8%), but felbinac was distributed to the 
muscle via the systemic circulation (>50%) (Table 2).[14] 
 
Contrary to Singh and RobertsÊ conclusions, Higaki et al. found 
that SA in the muscle layer was mainly from direct penetration 
(72.0%) and less from systemic distribution (28%).[14]  This is 
almost the reverse of Singh and RobertsÊ observations in1993 
(80% due to systemic blood supply, 20% due to direct 
penetration).[19]  Subsequent research confirmed that most of the 
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drug in muscle is due to direct migration and not from the 
systemic circulation following topical application.[30] 
Penetration Efficacy  
SA yielded the highest local tissue levels, followed by piroxicam, 
naproxen, indomethacin, and diclofenac (Table 4).  Note that 
aqueous solutions were used for estimating tissue concentrations, 
but in clinical practice, NSAIDs may be administered as partially 
nonaqueous creams, ointments, or gels. The observed 
differences may also reflect the differences in formulation, 
patches, application method (solution, ointment, or cream with or 
without rubbing), duration, application site, or species studied.[7] 
 
Table 4.   Estimated Concentrations of Various NSAIDs Found in Muscle at Maximal Flux 
Drug Fraction of Initial Concentrationa
Salicylic acid 10-6 
Piroxicam 10-7 
Naproxen 10-7.8
Indometacin 10-9.5
Diclofenac 10-9.7
Drug concentration found in muscle at maximal flux after topical, aqueous drug delivery.  
Singh and RobertsÊ estimated concentrations were obtained using pharmokinetic equations 
 and experimental kp values.  
aTaken from Singh and Roberts, Figure 6.[7] 
 
 
Table 5 examines the relative drug concentrations below the site 
of application and in the plasma of different studies.  In general, 
the results agreed with one another, though the relative 
concentration observed may be different.  This may be attributed 
to variations in topical application methods and the tissue location 
where the sample was taken.  Diclofenac, SA, ketoprofen, all 
have a greater concentration found in plasma than in muscle, 
where as naproxen has a higher drug amount in the muscle than 
in plasma. 
 
 
 
Table 5.   Comparison of NSAID Concentrations 2 h Following Topical Application *
 Reference Donor Cell Viable Skin Plasma Muscle 
Diclofenac 13 1 0.50μ0.02 (1.70μ0.09) x 10-3 (1.00μ0.05) x 10-3
 2 1 0.10μ0.01 (4.5μ0.2) x 10-3 (1.00μ0.05) x 10-3
Salicylic Acid 13 1 0.22μ0.01 (2.3μ0.1) x 10-2 (1.00μ0.08) x 10-2
 2 1 0.080μ0.004 (1.00μ.05) x 10-2 (2.50μ0.12) x 10-3
Ketoprofen 13 1 0.20μ0.01 (5.7μ0.3) x 10-3 (1.00μ0.15) x 10-3
Naproxen 2 1 0.08μ0.004 (2.5μ0.1) x 10-2 (4.00μ0.15) x 10-3
 26a 1(Epidermis) 0.22μ0.01(Dermis) (1.3μ0.1) x 10-3 (4.60μ0.23) x 10-3
The drug concentration profiles from the donor cell to the deep tissues from several experimental findings are compared.  
*Results are expressed as a fraction of initial donor cell or epidermis concentration. 
aConcentration profile taken 3 h postapplication.  
 
 
Distribution into Joints 
Diclofenac Controversy 
In a human study of percutaneous penetration into the joints, 
diclofenac gel was applied to one knee and a placebo gel to the 
other knee of patients with bilateral knee joint effusions.[31]  Drug 
distribution through synovial fluid was mainly through the systemic 
blood supply.  Direct penetration, if at all, was minimal.[31]  These 
results differ from other studies involving diclofenac, including the 
aforementioned study by Higaki et al., which found that 90.8% of 
diclofenacÊs distribution to muscle was due to direct 
penetration.[14] 
 
However, Higaki et al. used a six-compartment model based on 
steady-steady kinetics in collecting their data.  Other literature 
supports direct penetration as the main delivery mechanism for 
diclofenac, including one which observed 219.68 mg/mL of 
diclofenac in skeletal muscle allowing topical administration, 
whereas only18.75 mg/mL of the drug was found in plasma, 
where the study was also done in vivo patients, but diclofenac 
was applied to the anterior thigh.[32]  Recent study of diclofenac 
concentration in soft tissues after oral versus topical diclofenac 
administration in 14 patients prior to knee orthoplasty reported 
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that the diclofenac concentration was significantly lower in 
synovial membrane and synovial fluid in topically applied 
diclofenac than in oral administration (P=0.0181for topical 
diclofenac group  and P=0.004  for oral diclofenac group).  The 
authors could not identify the difference as the concentration-time 
curves of plasma and synovial tissues or the peak values after 
administration were not determined.[33]   On the contrary, using 
equivalent study methods and materials on 16 human subjects 
prior to ACL reconstruction surgery with the same study 
participation exclusion criteria, Kai et al. have found no significant 
difference in flurbiprofen concentration in synovial tissue after oral 
and topical administration of NSAID.  They postulated that the role 
of dermal vessels in the delivery of NSAID to the bone is reduced 
since the bone tissue is surrounded by a dense calcified 
matrix.[33-34] 
 
The minimal concentration of NSAID formulation that has anti-
inflammatory effects in the synovial tissue remains unknown.  
Additionally, the question of whether injection site and/or injection 
needle serve as contaminants in the studies ought to be given 
special attention.  Precision of measurement of diclofenac 
concentration inside the synovial tissue and plasma is imperative 
in drawing the appropriate conclusion of studies.  
 
Further investigations into this apparent contradiction of results 
are required, including whether the topical application site would 
make a difference as this has not been assessed properly to date 
to the best of our knowledge.  In addition, note that higher relative 
drug concentrations in the synovial fluid were measured in the 
smaller joints, such as finger and wrist joints, after topical delivery, 
which probably reflects the shorter diffusion distance that is 
needed to reach the deeper tissues. 
 
Difference in drug prescription, formulation and measurement play 
a role in the outcomes of all studies.  It is vital to collect more 
human data and develop more standardized animal/human 
models that will take into account not just one dimensional 
kinetics but the blood flow and lymphatic distribution of the 
microcirculation in the dermal layers of skin.  
Salicylic Acid 
SA penetrates into the synovial fluid. Rabinowitz et al. found high 
levels of salicylate in local tissues after transdermal application of 
its triethanolamine salt to knees of dogs.  After a 60 min 
administration period, 1.18μ0.84 mmol/g was found in the 
synovial fluid, significantly more than the 0.0094 mmol/g observed 
in serum.[35]  The greater tissue penetration of salicylate (used as 
a triethanolamine salt) is probably the result of the more lipophilic 
nature of TEA compared with SA.  Similarly, Mills et al. also 
demonstrated higher concentrations of SA and methyulsalicylate 
(MeSA), its commercial ester, in the synovial fluid after topical 
drug application to affected joints in greyhound dogs.  They used 
combined experimental procedure of micro dialysis and direct 
tissue concentrations to measure penetration of a commercial SA 
ester.  This technique allowed plasma drug concentration 
measurement from both systemic circulation and regional 
vascular drainage. Mills et al. credited direct diffusion and local 
blood redistribution to be responsible for the results.[36] 
Modes of Delivery  
In recent years, the delivery of SA following intracutaneous (i.c.), 
subcutaneous (s.c.), intramuscular injections (i.m.), and also after 
topical application were examined in rats.[37] A pharmacokinetic 
model was employed to calculate the rate constants between the 
skin, muscle, central, and peripheral compartments of the 
systemic circulation.  For calculations of intramuscular drug 
delivery, a two muscle compartment model was used, with the 
skin compartment eliminated.  The first order differential equations 
were also fitted to the concentration data of SA using the 
nonlinear least-square method.  However, for the i.c. and s.c. 
injection data, the fitted lines were a little bit higher than observed 
for early period measurements in the skin.[37]  From this 
observation, it appears that the first-order kinetics model for the 
drug migration may be too simple to express the complex 
migration process of SA.  However, the model should be sufficient 
to illustrate the general differences in skin dispositions of SA 
following i.c., s.c., and i.m., injections, as well as after topical 
application.  The group concluded that i.c. injection was the best 
for localizing the drug to the muscle while maintaining an effective 
drug concentration (Table 6).[37]  Their results corresponded with 
previous studies where most of the SA in the muscle following 
cutaneous injections was due to direct delivery from the injection 
site, and not from systemic redistribution. 
 
 
 
Table 6.   Salicylic Acid Clearance into Muscle for Various Delivery Routes*
Delivery Rate % Injected Dose Кsĉm 
i.c. injection 10μ 1 8.24 x 10-3 
s.c. injection 9μ 1 7.58 x 10-3 
i.m. injection 2.0 μ 0.1 2.94 x 10-3 
Topical application 1.0μ 0.1 4.95 x10-3 
The percent of the injected drug concentration found in the muscle 2h following  
delivery for different delivery routes are compared. Кsĉm  is the first-order rate  
constant from skin to muscle, obtained through curve-fitting using values obtained  
from several experiments.[37] 
 
  
 
Transdermal Drug Delivery Enhancements 
 
Benefits of transdermal delivery of drugs include the following:  
Pre-systemic metabolism is eliminated, which allows for reduction 
in the daily dosage levels. Blood or plasma levels of the drug can 
be retained within the therapeutic window for prolonged periods of 
time.  PatientÊs compliance is improved and the drug 
administration can be aborted by removal of the patch.  On the 
other hand the limitation is that the transdermal delivery only 
works for potent drugs with daily dose of the order of 10 mg or 
less. They must be „small‰ lipophilic molecules with molecular 
weight no greater than 500Da.  The drug must also be free of 
local irritation.  
Therefore, it comes as to no surprise that non-invasive 
approaches to enhance and control the drug transport in 
transdermal manner has been a hot topic for some time now.  
 
Those drug molecules that exceed the size of 500Da need 
enhancements to aid in their passing through the main security 
gate, SC barrier.  Most current tactics encompass: chemical 
penetration enhancers, iontophoresis, transporter carriers, 
ultrasound/microneedles/thermal poration.  
Transporter Proteins 
Transporter mechanisms have been implicated in affecting the 
drug absorption, disposition and elimination.  One such is a P-
glycoprotein (P-gp), a member of the ABC transporter family, was 
recently found expressed in human skin in addition to already 
known expression in other human tissues (liver, blood-brain-
barrier).  By comparing mRNA, protein expression and localization 
of P-gp in several skin tissues to human liver tissues, Skazik et al. 
determined strong P-gp protein expression within sweat ducts, 
vessels, nerve sheaths and most importantly muscles of human 
skin.[38] P-gp appears capable of transporting itraconazole within 
dermal tissue.  This new knowledge can possibly play a role in 
drug development and increasing the efficiency of delivery to 
specific sites in deep layers of skin such as muscles and joints.  
Data on this mechanism and deep penetration is in its early stage.  
Ultrasound guided percutaneous drug delivery 
High-frequency sonophoresis, HFS, (º 0.7 MHz) has been used 
for five decades to aid percutaneous delivery of corticosteroids.  
With the discovery of the cavitation effect within the skin that can 
impact skin permeability, thermal and convective effects can also 
play a role in increasing solute partitioning into the SC.  Most 
compounds delivered by HFS are small molecules, with only a 
handful of drugs having molecular weights greater than 1000 Da 
tested.  Because HFS is safe and FDA approved, many studies 
that include treatment protocols have been done testing the use of 
various drugs including NSAIDs and the efficacy of transdermal 
delivery.[39] 
 
Combination of iontophoresis, terpene and 
hypothermia 
Kigasawa et al. showed that using new iontophoresis device with 
terpene, like geraniol, in rats the percutaneous penetration of 
diclofenac was amplified.  Plasma concentration of diclofenac was 
increased 20-fold based on time-dependent delivery.  This new 
device uses an ion-exchange membrane that when combined with 
geraniol improves the penetration of diclofenac into the stratum 
corneum.  Overall there was no reported skin irritation.[40] 
Another study demonstrated the synergistic effect of iontophoresis 
and regional cutaneous hypothermia on trandermal delivery of 
diclofenac and prednisone to synovial fluid in rats. The study 
showed 3- fold increase in biovailability of both drugs by 
decreasing the dermal clearance of the drug via vasoconstrictive 
effects of hypothermic reaction.[41] The results of both studies are 
promising and warrant further investigation to determine the 
mechanism and efficacy in human subjects. 
Efficacy and Safety of Percutaneous Drug Delivery in 
Humans 
While research in humans regarding percutaneous drug delivery 
to muscle, tendon and joint is limited, more than a dozen studies 
assess the efficacy and safety of topical NSAIDs in several pain 
conditions.  Two randomized double-blinded controlled studies by 
Tugwell et al. and Simon et al. assessed efficacy and safety of a 
topical diclofenac solutions compared to an oral diclofenac 
solution, as well as the ability to alleviate the primary osteoarthritis 
symptoms in the knee in a 12 week period.  The first study by 
Tugwell et al. was performed on 622 female and male patients 
presenting with radiographic evidence of knee OA.  Three efficacy 
measures were pain, physical function and patient global 
assessment, which were measured on a nominal index scale.  
Results demonstrated no clinically significant difference between 
the two treatment arms in treating pain associated with 
osteoarthritis (p=0.10), asserting that a topical diclofenac solution 
is as effective as an oral diclofenac treatment.[42]  In the second 
study Simon et al. assessed pain scale, physical function as well 
as patient overall health assessment on ordinal scale.  The patient 
population consisted of 775 females and males also presenting 
with radiographic evidence of knee OA.  However, in addition to 
topical and oral diclofenac solutions the subjects were blindly 
given either placebo solution or a diclofenac solution in DMSO 
vehicle or a mixture of topical and oral diclofenac solutions.  The 
results were similar to the first study in that the efficacy of topical 
diclofenac was comparable to that of oral diclofenac treatment 
(p=.429).[43]  Overall both studies recommended that topical 
NSAIDs, specifically daclofenac, are indeed able to provide the 
therapeutic relief of osteoarthritis pain. Moreover, when 
comparing the safety of diclofenac in both studies, it is clear that 
topical diclofenac treatment demonstrated a lower incidence of GI 
side effects such as dyspepsia, diarrhea, abdominal distention, 
abdominal pain and nausea.  Treatment with oral diclofenac 
showed an association with significantly greater increases in liver 
enzymes and creatinine, and greater decreases in creatinine 
clearance and hemoglobin (p<0.001 for all).  The most common 
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adverse effect associated with topical diclofenac solution was dry 
skin.  In fact the dryness and irritation of the skin was similar in 
patients receiving the vehicle alone and topical solution with 
DMSO vehicle.  This finding might be possibly explained by the 
fact that vehicle dissolved lipids on the skin surface.[44]   
Typically, in clinical setting the use of emollients parallel to the 
main treatment of topical NSAID is encouraged but was not 
allowed in the trials.  Also, it was reported previously that DMSO 
can cause halitosis and body order in some patients as a result of 
its metabolite dimethyl sulfide producing a garlic-like order.[45] 
 
Elderly patients exhibit predisposition for topical NSAIDs based on 
the perception that a lower dose of the medication would result in 
less toxicity and would provide quick effect without affecting the 
rest of the body based on localized application.[46]   In order to 
elicit the best advice more longitudinal studies (>12 weeks) are 
needed with participants that have non-limited co-morbid 
conditions and concomitant medications.[47] 
New and Future Research Direction 
Photoacoustic Spectroscopy  
One limitation in human studies on topical penetration of anti-
inflammatory drugs is the inability to quantitatively and non-
invasively measure the formulation penetration rate through the 
tissue where the topical compound is applied.  Photo acoustic 
Spectroscopy (PAS) is one technique used in dermatological 
research to analyze the depth of penetration of a compound.  It 
has been shown to measure accurately penetration and 
distribution of various compounds through skin in vitro, ex vivo 
and in vivo.[48]  PAS measures the effect of absorbed light 
through the skin layers with and without the applied compounds.  
Oliveira et al. demonstrated with PAS that deep percutaneous 
infiltration of Helicteresgardneriana (EEHg) crude extract reduced 
significantly the croton oil-induced auricle inflammation in mice.  
Doses of 5.0mg and 7.5 mg of the EEHg created 61% and 75% 
decrease in edema of the auricle (P<0.001).  High resolution and 
the low cost and the effectiveness of PAS might be the future of 
instrumentalization of human dermatological research studies.[49] 
Compound Transdermal Patch 
Xi et al. explored the potential of compound transdermal patch 
containing teriflunomide (TEF) and lornoxicam (LOX), both 
recommended for treatment of rheumatoid arthritis (RA).  TEF is 
an active metabolite of leflunomide, a disease-modifying anti-
rheumatic drug (DMARD) and lornoxicam is a NSAID.  This is the 
first of its kind study examining compound topical agent for RA as 
it has not been investigated before in either animals or humans.  
The challenge is the delivery of drugs into the synovial tissues. Xi 
et al. first used in vitro permeation animal experiments to optimize 
the formulation of the compound patch and then delivered it to 
inflammation induced two knee joints of rabbits.  The goal was to 
observe whether the drug released into the articular cavity via 
direct diffusion on the application or via systemic circulation.  After 
applying the transdermal compound patch, authors noted the 
isochronous rates of penetration for TEF and LOX.  Moreover, 
direct diffusion of transdermal application of the patch with the 
medicine was more successful for the superficial joint tissues than 
for the deeper tissue synovial fluid as correlated to the drug 
concentration measured in the extracellular synovial fluid at 2h 
and 6h.  Additionally, drug concentrations were detected in the 
contralateral skin that did not receive the direct application of the 
transdermal patch.  This signified that the systemic blood supply 
played part in it.  As with any topical application of patches there 
is a risk for the local area irritation.  This experiment also showed 
that applying the compound patch at non-inflammatory ski of the 
ratsÊ knee and abdominal skin was sufficient to have drugÊs 
concentration detected in the inflamed bilateral hind paws of each 
rat.[50]  These findings are important for future research as they 
continue to contribute to the next generation of researchers who 
like the idea of combining treatment methods to increase the 
efficacy for given disease.  The query of topical site application 
remains to be explored further with the next way of research 
studies.  
Improvements To Future Research 
Unequivocally all the studies presented above continue propelling 
forward the research on percutaneous drug penetration into 
deeper underlying tissues.  Recent findings of involvement of 
dermal blood flow, lymphatic flow and convective transport in the 
transdermal delivery mechanism of NSAIDs added another 
dimension to consider for researchers.  It is possible that the 
newly formulated physiological pharmokinetic model represents 
more sound explanation for variations of transdermal transport of 
NSAIDs to muscle, tendon and joint in handful human studies that 
have been completed thus far.  Perhaps the questions of direct 
versus indirect drug penetration should be attributed to 
percutaneous drug penetration into muscles, tendon and 
periosteal tissues rather than all the way to bone tissue.  A new 
classification including the contribution of local blood flow system 
might be useful in applying to mechanism of delivery of NSAIDs 
into bone tissues.  
 
Questions raised by the studies primarily focus on the need of 
standardization of study procedures and increase the number of 
human studies to reciprocate the findings from in vivo and in vitro 
animal studies.  t cannot be emphasized properly the imperative 
nature of development not only for longitudinal studies in studying 
the safety and efficacy of topical NSAIDs, but also appropriate 
study protocols that will focus on standardization of anatomical 
sites and techniques used to collect the data.  For instance, 
clinical techniques routinely used to clean or prepare skin can 
significantly affect the rate and extent of penetration of a topically 
applied drug.  This may sway the results and affect our precise 
understanding of the percutaneous drug delivery into deeper 
tissues.  Further investigations into the NSAIDs, diclofenac 
specifically, deep penetration needed in order to resolve the 
conflicting results concerning the drug distribution mechanisms.  
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Conclusion 
The current focus in research of transdermal drug transport 
remains on finding ways to effectively control drug dosing, as well 
as targeting and retention into the site of interest.  Taken together, 
topical therapy for deep tissues has demonstrated efficacy and 
safety advantage.  Yet much remains to be done to clarify the 
mechanisms so as to permit further clinical development of 
treatments of various chronic local conditions in muscles and 
joints.  Confirming the clinical relevance of animals will be a major 
step forward. 
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